News
Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science
Title: OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death Poster number: 6111 / …
OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug) and emerging Globo H science. OBI Pharma, Inc. (TPEx: 4174) today announced …
OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
OBI is eligible to receive up to US$ 200 million in total milestone payments and tiered double-digit royalties on net sales. OBI Pharma, Inc. (OBI), …
OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants
OBI Pharma Inc. (TPEx: 4174) announced today research results in the past six-months of their new COVID-19 Vaccine. The vaccine, named BCVax, has been proven …
OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424
SOLID TUMOR PATIENTS WITH HIGH GLOBO H OR AKR1C3 EXPRESSION WILL BE ENROLLED. TAIPEI, Taiwan, January 24, 2022 — OBI Pharma, a Taiwan biopharma company …